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BACKGROUND: Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy
has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how these drugs mediate
their response is not clearly understood.
METHODS: Transcriptome profiling was performed after 4 days of trastuzumab, pertuzumab and combination treatment in human
ovarian cancer in vivo. Signalling pathways identified were validated and investigated in primary ovarian xenografts at the protein level
and across a timeseries.
RESULTS: A greater number and variety of genes were differentially expressed by the combination of antibody therapies compared
with either treatment alone. Protein levels of cyclin-dependent kinase inhibitors p21 and p27 were increased in response to both
agents and further by the combination; pERK signalling was inhibited by all treatments; but only pertuzumab inhibited pAkt signalling.
The expression of proliferation, apoptosis, cell division and cell-cycle markers was distinct in a panel of primary ovarian cancer
xenografts, suggesting the heterogeneity of response in ovarian cancer and a need to establish predictive biomarkers.
CONCLUSION: This first comprehensive study of the molecular response to trastuzumab, pertuzumab and combined therapy in vivo
highlights both common and distinct downstream effects to agents used alone or in combination, suggesting that complementary
pathways may be involved.
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A number of targeted therapies are currently under intense clinical
evaluation for use in ovarian cancer due to the heterogeneity of the
disease and the poor prognosis of patients (Banerjee and Gore,
2009; Yap et al, 2009). One approach being investigated is the
potential of Human Epidermal growth factor Receptor (HER)
2-directed therapy, since increased HER2 (erbB2) expression has
been associated with poor survival and resistance to platinum-
based therapy (Serrano-Olvera et al, 2006) and preclinical data
support the concept of using these inhibitors (Takai et al, 2005;
Mullen et al, 2007). Both antibody (trastuzumab and pertuzumab)
and small tyrosine kinase inhibitor (lapatinib) approaches have
recently undergone clinical trials in this disease (Bookman et al,
2003; Burris et al, 2005; Gordon et al, 2006; Kaye et al, 2008; Rivkin
et al, 2008; Makhija et al, 2010). Trastuzumab has been evaluated in
high HER2 expressing ovarian cancer and in this group, while only
7.5% of patients showed a response, 39% demonstrated stable
disease (Bookman et al, 2003). Pertuzumab has shown a clinical
benefit rate of 14.5% when RECIST responders, CA125 responders
and stable disease at 6 months were combined (Gordon et al, 2006).
This led to several large phase II studies evaluating pertuzumab in
both platinum-resistant disease in combination with gemcitabine
(Makhija et al, 2010) and in platinum-sensitive disease (Kaye et al,
2008). Lapatinib (GW572016), a dual HER2/EGF receptor inhibitor,
has been studied in two combination studies alongside chemother-
apy and demonstrated antitumour activity (but also toxicity),
which again supports the concept of targeting HER2 in ovarian
cancer (Burris et al, 2005; Rivkin et al, 2008).
The antibodies trastuzumab and pertuzumab target different
epitopes of HER2 (Badache and Hynes, 2004) and have differing
modes of action (Franklin et al, 2004; Spector and Blackwell, 2009).
Trastuzumab binds to the juxtamembrane region of the extra-
cellular domain (ECD) of HER2 (subdomain IV) and in breast
cancer demonstrates best activity against HER2-overexpressing
disease. It has been shown to act through a variety of differing
mechanisms including antibody-dependent cellular cytotoxicity
(ADCC), inhibition of ECD cleavage, abrogation of intracellular
signalling, reduction of angiogenesis and decreased DNA repair
(Spector and Blackwell, 2009). Pertuzumab is an HER2 dimerisa-
tion inhibitor that binds to HER2 near the centre of domain II, the
dimerisation domain (Franklin et al, 2004). Unlike trastuzumab,
the effects of pertuzumab do not strictly require HER2 over-
expression and therefore pertuzumab may be a better choice
against tumours expressing HER2 at a lower level. For example,
pertuzumab inhibits heregulin-stimulated growth mediated by
HER2/HER3 dimers of breast cancer cells, whereas trastuzumab is
more efficient at growth inhibition in the absence of heregulin
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(Lee-Hoeflich et al, 2008). Besides inhibition of dimerisation,
pertuzumab mediates ADCC in a similar way as mentioned above
for trastuzumab (Clynes et al, 2000). A recent study demonstrated
enhanced antitumour activity of trastuzumab and pertuzumab
combination in HER2-positive NSCLC (Calu-3) and breast cancer
(KPL-4) xenograft tumour models (Scheuer et al, 2009). Results
from the clinical evaluation of pertuzumab and trastuzumab
(CLEOPATRA) study have demonstrated that addition of pertu-
zumab to trastuzumab plus docetaxel extended progression-free
survival from 12.4 to 18.5 months for HER2-positive metastatic
breast cancer indicating the clinical benefit from combination of
these two antibodies (Baselga et al, 2012).
To identify which patients will respond to these agents either
alone or in combination, there is a need to characterise the
molecular response and identify predictive biomarkers to guide
treatment selection. Gene expression profiling has previously been
used to characterise the effects of different agents in vivo (Taylor
et al, 2010).
This study is the first to define the molecular response to
trastuzumab and pertuzumab in ovarian cancer in vivo. We assessed
the effects of the treatments on gene expression, proliferation and
apoptosis in SKOV3 xenografts, both individually and in combina-
tion. Potential biomarkers and pathways were validated by
quantitative real-time PCR (qRT–PCR). Changes in gene expression
were evaluated at the protein level and then across a panel of primary
ovarian xenografts. Together, these studies provide insight into the
mechanisms of trastuzumab and pertuzumab in ovarian tumours,
which may also be applicable to other cancers.
MATERIALS AND METHODS
Xenografts
Adult female nu/nu mice were implanted subcutaneously with
SKOV3 tumour fragments (previously established from the cell
line) or primary ovarian tumour fragments in the flanks and
allowed to grow to 4–6mm in diameter (over a period of B1
month). Animals were at least 8 weeks old at the time of
experimentation and were maintained in negative pressure
isolators (La Calhene, Cambridge, UK). The mice were treated with
trastuzumab (20mg/ kg 1), pertuzumab (20mg/ kg 1) and
trastuzumabþ pertuzumab (20mg/ kg 1 each). Drugs were given
via the intraperitoneal route in saline on days 0, 3, 7 and 10.
Tumour size was measured twice weekly using calipers and the
volume calculated according to the formula p/6 lengthwidth2.
Relative tumour volumes (%) were then calculated for each
individual tumour by dividing the tumour volume on day t (Vt) by
the tumour volume on day 0 (V0) and multiplying by 100.
The histological subtypes of the ovarian cancers from which
the xenografts were derived were as follows: HOX 493 and
OV1002 – serous histology; HOX 424 – mixed clear cell/
endometrioid histology; HOX 516 and HOX 486 – mixed serous/
endometrioid histology.
Gene expression profiling and analysis
Total RNA was prepared from 10 to 50mg of frozen tissue after 4
days of treatment, preincubated with RNAlater-ICE (Ambion,
Austin, TX, USA) using the miRNeasy Mini kit (Qiagen, Hilden,
Germany) and TissueRuptor (Qiagen) following manufacturers’
instructions. The RNA quality was checked by the RNA 6000 Nano
assay on the Agilent Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). RNA integrity numbers were 48.5. All samples
were divided into two identical aliquots for independent labelling
and hybridisation. Total RNA for each sample ( 0.5 mg) was
amplified and biotinylated using the Illumina TotalPrep RNA
Amplification Kit (Ambion) according to manufacturers’ standard
procedure. This procedure consists of reverse transcription with
an oligo(dT) primer bearing a T7 promoter using a reverse
transcriptase (RT). The quality and quantity of cRNA in the
samples was checked with an Agilent Bioanalyzer 2100 (Agilent
Technologies), samples were diluted to 150 ng/ml 1 and hybri-
dised to Illumina HT-12 BeadChips in duplicate (Illumina, San
Diego, CA, USA).
Microarray data analysis was performed using the statistical
programming language R and Bioconductor packages. Illumina
probe profile expression values were subjected to quantile
normalisation using the lumi package. Differentially expressed
genes were identified using Significance Analysis of Microarrays
(SAM; Tusher et al, 2001), implemented with the siggenes package.
Centred average linkage clustering was performed using the
Cluster and TreeView programs as described previously (Eisen
et al, 1998). The online Database for Annotation, Visualisation and
Integrated Discovery (DAVID) programme (Huang da et al,
2009) was used to identify overrepresented KEGG (Kyoto
Encyclopaedia of Genes and Genomes) pathways from lists of
differentially expressed genes. Raw and processed gene expression
files have been submitted to NCBI Gene Expression Omnibus
(https://www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE31432.
Western blot analysis
Xenografts were lysed in 50mM Tris pH 7.5, 150mM NaCl, 1%
Triton X-100, 5mM EGTA, 10 mgml 1 aprotinin (Sigma-Aldrich,
St Louis, MO, USA), Complete Protease Inhibitor Cocktail (Roche,
Basel, Switzerland) and Phosphatase Inhibitor Cocktail 1 and 2
(Sigma-Aldrich) and spun for 10min at 16 000 g at 41C. The protein
content of the resulting supernatant was determined by the
Bicinchoninic acid protein assay (Sigma-Aldrich). Protein lysates
were electrophoretically resolved on 7.5–10% SDS–PAGE and
transferred onto Immobilon-P membranes. After transfer, mem-
branes were blocked with 1% blocking agent (Roche) in TBS before
probing overnight at 41C with the appropriate primary antibody.
Antibodies used for western blotting were as follows: anti-
phosphorylated HER1 (pHER1) (Tyr992; Cell Signaling Technology,
Danvers, MA, USA) at 1 : 1000; anti-phosphorylated HER2 (pHER2)
(Tyr877; Cell Signaling Technology) at 1 : 1000; anti-phosphorylated
HER3 (pHER3) (Tyr1289; Cell Signaling Technology) at 1 : 1000 and
anti-actin (Merck, Whitehouse Station, NJ, USA). For detection of
the ECD of HER2, NeoMarkers c-erbB2 antibody Ab-20 (MS-1350)
was used while the Dako anti-HER2 antibody from the Hercept test
was used to detect the C-terminal domain. Immunoreactive bands
were detected using enhanced chemiluminescent reagents (Roche)
and Hyperfilm enhanced chemiluminescence film (Amersham,
Little Chalfont, Buckinghamshire, UK). Integrated absorbance
values were obtained by densitometric analysis using a gel scanner
and analysed by Labworks gel analysis software (UVP Life Sciences,
Cambridge, UK).
Quantitative RT–PCR
RNA (1 mg) was reverse transcribed using QuantiTect Reverse
Transcription kit (Qiagen) according to manufacturers’ instruc-
tions, 100-fold dilutions were used, except for primers KLK11,
transforming growth factor, b-induced (TGFBI) and PTPRR for
which a 10-fold dilution was used. The amount of cDNA was
quantified using Rotorgene (Corbett Research, San Francisco, CA,
USA) and the QuantiTect SYBR Green system (Qiagen) according
to manufacturers’ instructions. Primers were from Qiagen, except
KLK11 (Sigma-Aldrich), PCRs on RNA samples which had not
been reverse transcribed were also carried out to check for
genomic DNA contamination, these were all negative. The
housekeeping gene GUSB was used as a reference gene, as its level
was constant across the microarray results.
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Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) for SKOV3 (four replicates) and
primary tumour (two cores each) xenografts were produced using
previously described techniques (Kononen et al, 1998). Haematox-
ylin and eosin sections of the tumour xenografts were reviewed by a
pathologist and representative areas marked. Recipient blocks were
prepared by melting paraffin and pouring into a 5- to 10-mm-thick
mold. Immunohistochemistry was performed using a standard
immunoperoxidase procedure. Sections were dewaxed and rehy-
drated before proceeding with antigen retrieval under pressure for
5min in sodium citrate buffer (8.2mM citric acid, 1.8mM sodium
citrate, pH 6) or Tris-EDTA buffer (10mM Tris, 1mM EDTA, 0.05%
Tween-20, pH 9). The slides were then treated with 3% H2O2 for
10min to quench peroxidase activity. Subsequently, they were
incubated in serum-free block solution (Dako, Glostrup, Denmark)
for 20min to eliminate any unspecific background staining. Primary
antibody incubations were Ki67 (DAKO; M7240) at 1 : 50; phospho-
Histone H3 (Cell Signaling Technology; 9701) at 1 : 100; p27 (Cell
Signaling Technology; 2552) at 1 : 100 for 1 h at room temperature;
p21 (Cell Signaling Technology; 2946) at 1 : 100; anti-phosphorylated
ERK (pERK) 1/2 (Cell Signaling Technology; 9101) at 1 : 25; anti-
phosphorylated Akt (pAkt; Ser473; Cell Signaling Technology; 4060)
at 1 : 100; cleaved caspase 3, (#9661 Cell Signaling Technology;
1 : 200) were used overnight at 41C. EnVision (HRP Rabbit/Mouse;
Dako) was used as secondary antibody and positive staining was
detected by incubation with 3,3-diaminobenzidine solution (DABþ
chromogen; Dako). Finally, the sections were counterstained with
haematoxylin, dehydrated and mounted. Quantification of positivity
(0–100%) was based on an estimate of the percentage of
immunoreactive tumour cells in the cores. For staining with cleaved
caspase 3, phospho-histone H3 and p21, the immunoreactive nuclei
were counted and divided by the total amount of tumour cell nuclei
in each core. Statistical analysis of data obtained by immunohis-
tochemistry was performed using the Mann–Whitney U-test.
AQUA automated image analysis
A detailed description of the AQUA HistoRx methodology is
available elsewhere (Camp et al, 2002; Aitken et al, 2010).
Pan-cytokeratin antibody was used to identify infiltrating tumour
cells, DAPI counterstain to identify nuclei, and Cy-5-tyramide
detection for target for compartmentalised (tissue and subcellular)
analysis of tissue sections. Monochromatic images of each TMA
core were captured at  20 objective using an Olympus
AX-51 epifluorescence microscope (Olympus, Southend-on-Sea,
UK), and high-resolution digital images analysed by the AQUA-
nalysis software (HistoRx, Branford, CT, USA). When whole tissue
sections of xenograft tumours were analysed, the whole section
was divided into  20 objective magnification images and an
AQUA score generated for each frame for heterogeneity analysis.
Briefly, a binary epithelial mask was created from the cytokeratin
image of each TMA core. If the epithelium comprisedo5% of total
core area, the core was excluded from the analysis. Similar binary
masks were created for cytoplasmic and nuclear compartments
based on DAPI staining of nuclei. Target expression was quantified
by calculating the Cy5 fluorescent signal intensity on a scale of
0–255 within each image pixel, and an AQUA score was generated
by dividing the sum of Cy5 signal within the epithelial mask by the
area of the cytoplasmic compartment.
HER2 FISH
Gene amplification of HER2 was assessed by FISH using the
Pathvysion HER2 DNA Probe Kit (Vysis, Downers Grove, IL,
USA). The HER2 to CEP17 ratios of 42.0 were considered
amplified.
RESULTS
Common molecular responses to trastuzumab,
pertuzumab and combination therapy
Human epidermat growth receptor 2-expressing SKOV3 ovarian
cancer xenografts were treated with trastuzumab alone, pertuzu-
mab alone or combined antibody therapy. Pertuzumab slowed
growth, whereas trastuzumab and combination treatment resulted
in stronger growth inhibition, with the combination being most
potent, giving a significant (Po0.05) reduction in tumour volume
by day 4 (Figure 1A). Differentially expressed genes after 4 days of
treatment compared with untreated SKOV3 tumour xenografts
were identified using the SAM approach (Tusher et al, 2001) with a
10% false discovery rate (FDR). Similar numbers of probes were
differentially expressed (105 and 113) in response to either
trastuzumab or pertuzumab alone, compared with untreated
tumours (Figure 1B). Almost all the significantly changed genes
were upregulated (94% and 98%) in tumours subjected to a single
agent. Many more probes (555) were differentially expressed
between the combination therapy and control groups, of which
just over half were upregulated (55%; Figure 1B). There was greater
overlap (Figure 1C) between the genes differentially expressed by
trastuzumab alone and the combination therapy (6%) than
between pertuzumab alone and the combination (2%), which
may relate to the more similar reduction in tumour volume
observed (Figure 1A; full gene lists in Supplementary File 1). The
KEGG pathways that were overrepresented by the gene lists
identified using DAVID (Huang da et al, 2009) are shown in
Table 1. Prominent among the gene lists for trastuzumab and
pertuzumab single agent treatments were genes involved in the
well-characterised p53, MAP kinase and not surprisingly (but
reassuringly) the HER (ErbB) signalling pathways, including the
FOS, JUN, DUSP1, SERPINB5, p53AIP1, HER3 and CDKN1A (p21).
Different genes and pathways are activated or repressed in
response to anti-HER2 agents
Several distinct patterns of gene expression could be seen between
the two treatments alone or in combination. Ten genes with
differing patterns of expression across the treatments were
validated by qRT–PCR, the fold changes were highly consistent
with those established from the Illumina data, with a correlation
coefficient (R2) of 0.97 (Po0.0001; Supplementary Figure 1). Many
of the genes that were most differentially expressed by combina-
tion therapy were also altered in trastuzumab-treated tumours,
albeit to a lesser extent (FDR 410%; Figure 1D). These genes
include the highly expressed serine protease, hippostasin (KLK11),
oestrogen receptor a (ESR1) and the classic E2-response genes
TFF2 and TFF3 (TFF1 had a similar pattern of expression (Pearson
correlation coefficient R¼ 0.72), but was not among those with an
FDRo10%), along with E-cadherin (CDH1), see Figure 1D and
Supplementary Figure 1. The same criteria as above (SAM
FDR¼ 10%) was used to identify 119 genes whose expression
was different between the response to the two agents administered
separately. Two-thirds (80 out of 119) of these genes were higher
following trastuzumab than pertuzumab treatment, although axon
guidance was the only KEGG pathway highlighted (Table 1). Genes
with discordant expression between the two agents were much
more strongly correlated between trastuzumab and combination
(Pearson R2¼ 0.73, Po0.0001) than between pertuzumab and
combination (R2¼ 0.03, P¼ 0.14). This is consistent with the
observation that the effects of trastuzumab dominate the molecular
response when the agents are administered given together
(Figure 1D). It was interesting to note that genes involved in
chemokine/cytokine-receptor interactions (IL1A, IL6, IL8, CXCL1,
CCL2, CCL26, IL4R, IL11RA) and genes associated with cell
communication (CD40, CLDN1, PECAM1, VCAM1) were increased
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following the treatment with pertuzumab, but were reduced
following the treatment with trastuzumab and reduced further
with the combination. Examples of genes that were more down-
regulated after combination therapy compared with either agent
alone and validated with qRT–PCR were interleukin 8 (IL8) and
TGFBI. A number ofkeratins (KRT6A, 8, 14, 16, 17, 19) and
laminins (LAMC2, B3 and A3) associated with cell adhesion were
more strongly increased by treatment with single agents than
combination therapy. Genes of the MAPK signalling pathway
including FOS and DUSP1 were more strongly induced by
pertuzumab, while certain genes including ectonucleotide pyr-
ophosphatase 2 (ENPP2) and matrix metalloproteinase 7 (MMP7)
were only changed by the combination and not by single agents
(Figure 1D; Supplementary Figure 1).
Comparison of the transcriptomic response to previous
studies of anti-HER agents
Eight of the sixteen genes identified as downregulated in SKBR3
and BT474 breast cancer cells in vitro following the trastuzumab
treatment (Le et al, 2005a) were also significantly (t-test, Po0.05)
repressed by trastuzumab in this study (RFC4, BUB1B, SPAG5,
AURKA, UBE2C, ZWINT, TYMS and FEN1), but only three genes
were repressed by pertuzumab (RFC4, BUB1B and HMGB2) and
the combination (RCF4, BUB1B and FEN1). The fact that these
genes were not among those most significantly differentially
expressed genes in our study (Supplementary Figure 2A) is likely
to be a reflection of the more variable and complex responses
observed in vivo. Indeed, a microarray study of responding and
non-responding patients with locally advanced HER2-positive
breast cancer treated with trastuzumab combined with docetaxel
found that gene expression of classical cancer pathway genes
related to apoptosis or DNA repair could not distinguish
responding tumours (Vegran et al, 2009). Of the 28 genes not
involved in classical cancer pathways that were used to predict
response, only 4 (of the 25 out of 28 genes represented by our
data) were commonly significantly upregulated/downregulated
(Supplementary Figure 2B).
HER receptor phosphorylation and downstream signalling
To better understand the effects of trastuzumab, pertuzumab and
the combination on activated HER receptor signalling, we first
checked the phosphorylation status of HER2, together with its
heterodimer partners HER1 and HER3. After 14 days of treatment,
HER2 phosphorylation at Tyr877, an Src-dependent phosphoryla-
tion site, was increased in pertuzumab-treated tumours
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Control Trastuzumab Pertuzumab Combination
Figure 1 Common and differential molecular responses to trastuzumab and pertuzumab alone or in combination. (A) Reduction in tumour volume
upon treatment with trastuzumab or pertuzumab or combination after 4 days, relative to day 0. Mean relative tumour volume of SKOV3 tumour xenografts,
n¼ 3, error bars represent standard deviation (*Po0.05). (B) Comparison of the number of differentially expressed genes with either agent or combination
therapy relative to control, using SAM with 10% FDR cutoff. Red¼ upregulated, green¼ downregulated. (C) Venn diagram showing the overlap between in
genes that were significantly differentially expressed between trastuzumab, pertuzumab and combination therapy (SAM FDR¼ 10%) after 4 days of
treatment. The sizes of circles and overlaps are only roughly proportional to the number of genes. (D) Heatmap showing relative expression of 697 genes
from Venn diagram, red represents increased expression and green decreased expression relative to the median of the controls.
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Table 1 KEGG pathways overrepresented by genes differentially expressed with an FDRo10% (see Figure 1D and full list in Supplementary File 1)
KEGG pathway Genes P-value FDR
Trastuzumab compared with control (105 probes)
ErbB signalling pathway PAK6, CDKN1A, NRG4, ERBB3 0.002 1.6
p53 signalling pathway P53AIP1, CDKN1A, SERPINB5 0.06 47.2
Pertuzumab compared with control (113 probes)
p53 signalling pathway CDKN1A, SERPINB5, CD82, SFN, GADD45A 0.003 2.7
Renal cell carcinoma PAK6, CDKN1A, EPAS1, JUN, PAK1 0.003 3.0
ErbB signalling pathway PAK6, CDKN1A, JUN, PAK1 0.006 6.4
Focal adhesion PAK6, CDKN1A, LAMA3, TNC, JUN, PAK1 0.007 7.1
T-cell receptor signalling pathway PAK6, FOS, CDKN1A, JUN, PAK1 0.01 13.1
MAPK signalling pathway FOS, DUSP1, ARRB1, JUN, PAK1, GADD45A,IL1A 0.03 23.7
Pathways in cancer JUP, FOS, CDKN1A, LAMA3, EPAS1, JUN 0.06 47.7
Combination compared with control (555 probes)
Arginine and proline metabolism NOS1, CKM, ASS1, GLS, ALDH3A2 0.01 12.2
Metabolism of xenobiotics by cytochrome P450 GSTA1, GSTA2, CYP2S1, UGT2A3, UGT2B15,ALDH3A1 0.02 19.4
Glycerolipid metabolism LIPG, MGLL, GK, ALDH3A2, AGPAT2 0.03 27.8
Epithelial cell signalling in Helicobacter pylori infection CXCL1, IL8, JUN, ATP6V1E2, RAC1, ATP6V0A2 0.03 29.7
Ascorbate and aldarate metabolism UGT2A3, UGT2B15, ALDH3A2 0.07 57.1
Drug metabolism GSTA1, GSTA2, UGT2A3, UGT2B15, ALDH3A1 0.07 59.4
Pathways in cancer IL6, FGFR3, IL8, FOXO1, KITLG, CDH1, FZD7, JUP, CDKN1A,
RASSF5, LAMC3, JUN, RAC1, LAMC2
0.07 60.2
Bladder cancer CDKN1A, FGFR3, IL8, CDH1 0.09 67.9
Starch and sucrose metabolism PYGL, GK, UGT2A3, UGT2B15 0.09 67.9
D-glutamine and D-glutamate metabolism GLS 0.09 70.8
Trastuzumab-treated compared with pertuzumab treated (119 probes)
Axon guidance ABLIM1, SRGAP3, SEMA4C 0.05 38.9























































































































Figure 2 HER receptor signalling. Phosphorylation of human epidermal growth factor receptors (HERs) 1, 2 and 3 after 14 days of therapy and control
as detected by western blotting (A). Anti-HER2 C-terminal western blotting using day 14 tumours showed two bands, p185 and p95, but anti-extracellular
domain (ECD) of HER2 blotting revealed another band (p110) consistent with the ECD produced by shedding from full-length HER2 (B). Anti-ECD and
anti-C-terminal antibodies after 14 days in whole tissue sections using quantitative immunofluorescence (C). The ECD to C-terminus ratio (D) was
increased in trastuzumab-treated groups (alone or combined), suggesting that increased shedding inhibited by trastuzumab.
Molecular response to trastuzumab and pertuzumab
AH Sims et al
1783





















HER1, but not HER3 (Figure 2A and B) consistent with in-vitro
studies (Le et al, 2005a; Lee-Hoeflich et al, 2008). Although it is
currently unclear whether increased phosphorylation activates
downstream signalling, this might be one of the reasons why the
combination is more effective because trastuzumab reduced the
phosphorylation. It is also consistent with the mechanism of
pertuzumab shown by previous studies that it does not block
signals from HER1 homodimers or HER1–HER3 heterodimers
(Burris et al, 2005; Vegran et al, 2009). There were both similarities
and differences between the genes that were differentially
expressed in our study and those highlighted by a recent gene
expression study (Ghosh et al, 2011) of HER2 homodimers and
HER2/HER1 or HER2/HER3 heterodimers in HER2-expressing
MCF10A cells (Supplementary Figure 2C and D), which may
indicate cell- or disease-specific signalling. Anti-HER2 C-terminal
blotting using day 14 tumours showed two bands, p185 and p95
(Figure 2B). The p95 band is well described in breast cancers and
hypothesised to contribute to trastuzumab/pertuzumab resistance,
but in ovarian cancer little is known. Anti-ECD of HER2 blotting
revealed another band (p110) consistent with the ECD produced
by shedding of full-length HER2 (Figure 2B). This observation led
us to examine HER2 population expression by both anti-ECD and
anti-C-terminal antibodies on the 14 day whole tissue sections
using quantitative immunofluorescence (Figure 2C). The ECD to
C-terminus ratio (Figure 2D) was increased in trastuzumab-treated
groups (alone or combined), suggesting that increased shedding is
inhibited by trastuzumab, which is consistent with one of the
proposed mechanisms of action of trastuzumab (Badache and
Hynes, 2004). Two pathways thought to be involved in the
response to the HER2 inhibitors, ERK and Akt were assessed by
phosphoprotein assay. Pertuzumab alone reduced expression of
pAkt, while both antibodies and the combination reduced
expression of pERK after 4 days (Figure 3A).
Time-course analysis of trastuzumab and pertuzumab
treatment at protein level
Tissue microarrays were constructed from four cores from three
different SKOV3 xenografts to analyse changes in protein level at
five time points from the beginning of the treatment (days 1, 2, 4, 7
and 14). Quantitation of pAkt and pERK using AQUA quantitative
immunofluorescence confirmed the immunohistochemical obser-
vations (Figure 3). The levels of Ki67, phospho-histone H3 and
cleaved caspase 3 were measured to assess changes in proliferation,
cell division and apoptosis. Expression of the markers was
somewhat variable across the time points, but was largely
consistent using immunohistochemistry (Figure 4). The changes
in Ki67 and phospho-histone H3 expression upon treatment of
SKOV3 xenografts were not significant; however, combination
treatment with trastuzumab and pertuzumab resulted in more
apoptotic cells during the first few days of therapy, as seen by an
increase in cleaved caspase 3 (Figure 4). The gene expression level
of cyclin-dependent kinase (CDK) inhibitor 1A (CDKN1A/p21)
was upregulated by all treatments (Figures 1 and 4). The level of
p21 protein appeared to be greatest after 7 days of pertuzumab
therapy compared with trastuzumab or combination (Figure 5).
The protein level of CDK-inhibitor 1B (p27/CDKN1B) was
significantly increased in response to both trastuzumab and the
combination treatment (Figure 4), but the gene expression level
























































































































Figure 3 Pertuzumab reduces phospho-AKT, but phospho-ERK is reduced by either drug or combination. Assessment of phospho-AKT (A) and
phospho-ERK (B) in SKOV3 xenograft tumours after 7 days using immunohistochemistry. Assessment of phospho-AKT (C) and phospho-ERK (D) in
SKOV3 xenograft tumours across a time course using AQUA quantitative immunofluorescence. *Po0.05 Student’s t-test of treatment relative to control.
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Figure 4 Effect of single or combination therapy on proliferation, cell cycle, apoptosis and protein markers over time. Total and phosphoprotein levels
were determined by immunohistochemistry of TMAs for Ki67, phopho-histone H3, cleaved caspase 3, p21 and p27. See Supplementary Figure 3 for



















































































































































































































Figure 5 Combination therapy is more effective than either agent alone in a primary tumour. The primary ovarian xenograft HOX424 shows
significantly greater growth inhibition to combined trastuzumab and pertuzumab treatment than to either agent alone. Total and phosphoprotein levels were
determined by AQUA quantitative immunofluorescence of TMAs for Ki67, phospho-histone H3, p21, p27 and phospho-AKT after 24 days. *Po0.05
Student’s t-test of treatment relative to control.
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Differential response to combination therapy in a panel of
primary ovarian cancer xenografts
We previously established that response to combined antibody
therapy (trastuzumab plus pertuzumab) was variable across a
panel of five xenografts derived from primary ovarian tumours or
ascites (Faratian et al, 2011). The xenograft model (HOX 424) with
the highest HER2 protein expression and the biggest increase in
HER3 on treatment had a complete response to treatment with the
combined antibodies, two xenograft models showed a partial
response (HOX516 and HOX486) and two were unaffected by
treatment (HOX493 and OV1002) (Faratian et al, 2011). Human
epidermal growth factor receptor 2 FISH was undertaken on these
five xenografts together with the SKOV3 model and HER2 gene
amplification was observed in the two responsive xenograft
models, HOX 424 and SKOV-3, but not in the other four xenograft
models (Supplementary Figure 3). HOX 424 xenografts demon-
strated a 7.8-fold amplification of HER2 while SKOV3 was 2.2-fold
amplified, consistent with previous reports (Rhodes et al, 2002).
Expression of EGFR (HER1) was also investigated, but showed no
consistent change on treatment (Figure 6). These results are
consistent with the view that this combination of antibodies is
likely to be most effective in HER2-amplified cancers.
To further understand the effects of the two agents, HOX424 was
subjected to both antibody treatments alone and in combination.
We found that growth of the HOX424 xenograft tumours was
significantly reduced when treated with the combination therapy,
but not by either agent alone (Figure 5). There was significant
reduction in Ki67 in the trastuzumab and (greater) in the
combination treated tumours. Phospho-histone H3 was also
reduced, most greatly in the trastuzumab-treated tumours
(Figure 5). Levels of p21 and p27 were only increased with the
combination, perhaps reflecting the synergistic effect of the agents.
As in the SKOV3 xenografts, pertuzumab alone significantly
reduced expression of pAkt (Figure 5). The level of pERK was
unchanged by either treatment alone or in combination (data not
shown); however, this may have been due to the rather late single
time point at 24 days.
To ascertain the further applicability of our results, we examined
the effect of trastuzumab and pertuzumab combination therapy on
proliferation, apoptosis, cell division and cell cycle across all five
xenografts. Quantification by immunohistochemistry and AQUA
quantitative immunofluorescence methods was highly consistent.
Ki67 was found to be markedly decreased in HOX424 and
HOX516; these tumours also showed decreases in cleaved caspase
3. The mean level of phospho-histone H3 was increased in OV1002,
but decreased in HOX424 (Figure 6). In contrast to the increase in
CDK1NA gene expression in SKOV3 cells after 4 days (Figures 1
and 2), the nuclear protein expression of p21 was reduced in
HOX424 and HOX486 following the combination therapy
(Figure 6). The level of p27 was clearly increased in the three
ovarian xenografts models that responded well to combination
treatment, although HOX516 was unchanged that may be
consistent with only a tempory reduction in tumour volume at
day 4, before increasing by day 7 (Figure 6). Levels of pAKT and


























































































































































































































ControlT + P T + P
Figure 6 Differential responses to combination therapy in a panel of primary ovarian xenografts. Five human xenografts grown from material obtained
primary ovarian cancer patients were treated with the trastuzumab plus pertuzumab combination. HOX424 displayed a complete growth response,
HOX516 and HOX486 show a minor response and HOX493 and OV1002 were unresponsive. Xenografts were collected on day 7. Mean values (±s.e.)
of at least four tumours/group are shown. Dashed lines show changes for immunohistochemistry, solid lines for AQUA quantitative immunofluorescence.
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Although trastuzumab and pertuzumab target different epitopes of
HER2 (Badache and Hynes, 2004) and have differing modes of
action (Franklin et al, 2004; Spector and Blackwell, 2009),
downstream signalling and the molecular response to anti-HER2
antibodies has not previously been clearly characterised in any
cancer setting in vivo. In this study, for the first time we
comprehensively examine the molecular response to two impor-
tant anticancer agents alone or in combination, both in terms of
the transcriptome and key markers of established pathways,
proliferation, apoptosis, cell division and cell cycle at the protein
level. Induction of p27 has previously been described as one of the
key modes of action of HER2-targeting antibodies in breast cancer
(Le et al, 2005b), with an increase thought to cause proliferating
cells to exit the cell cycle and induce apoptosis. Downregulation of
p27 has been associated with trastuzumab resistance in breast
cancer cells (Nahta et al, 2004b). The level of p27 expression in
SKOV3 xenografts in this study was primarily increased after
combination treatment. Gene expression level of p27 was
apparently not increased, but the level of p21 was significantly
higher following all treatments. Cyclin G2 has previously been
shown to be upregulated following the trastuzumab treatment in
BT474 cells in vitro and in vivo (Le et al, 2007); it was also
upregulated by trastuzumab in this study, but was downregulated
by pertuzumab (Supplementary Figure 2A). The growth arrest
response gene GADD45A was increased by all treatments and is
known to be induced following the growth arrest conditions,
resulting in cell-cycle arrest (Jiang et al, 2003).
Gene expression profiling of SKBR3 and BT474 breast cancer
cells in vitro has suggested that trastuzumab downregulates genes
of the cell cycle, cell growth, cell maintenance, and chromatin
structure (Le et al, 2005a). Neoadjuvant trastuzumab treatment has
previously been shown to induce apoptosis in primary breast
cancers (Mohsin et al, 2005). However apoptosis-related genes
were not able to distinguish between responding and non-
responding trastuzumab-docetaxel breast tumours (Vegran et al,
2009). A study of treatment with pertuzumab and/or trastuzumab
resulted in a reduced fraction of proliferating cells, prolongation of
G1 phase and a great increase in quiescent BT474 cells with either
agent, but did not induce an appreciable amount of apoptosis in
either BT474 or SKBR3 cells (Brockhoff et al, 2007). KLK11 was
among the highest upregulated genes for the combination therapy
and has previously been found to predict unfavourable prognosis
in ovarian cancer (Shigemasa et al, 2004).
Cytokines and chemokines have a lead role in cancer-related
inflammation, promoting tumour cell survival, proliferation and
metastasis (Germano et al, 2008). In this study, pertuzumab
treatment appeared to stimulate an inflammatory response,
whereas trastuzumab or the combination treatment suppressed
the process, which is more consistent with the immunoreactive
actions previously noted through ADCC (Arnould et al, 2006). A
number of laminins and keratins were differentially expressed
upon treatment. These are known to promote cell adhesion,
migration, protease activity, proliferation, tumour growth, angio-
genesis and metastasis (Engbring and Kleinman, 2003).
Trastuzumab and pertuzumab combination therapy has been
shown to provide enhanced antitumour activity in non-small cell
lung (Scheuer et al, 2009), breast (Baselga et al, 2012) and now in
ovarian cancer xenografts; however, it is not entirely clear how
these drugs may complement each other. The expression of genes
that had discordant expression between the two agents correlated
much more strongly between the trastuzumab and the combina-
tion than between pertuzumab and combination, demonstrating
that the molecular response to trastuzumab dominates, consistent
with the changes in tumour volume and apoptosis.
The synergistic action of trastuzumab and pertuzumab combi-
nation treatment was previously shown in vitro to be mediated by
enhanced disruption of receptor dimers, leading to increased
apoptosis (Nahta et al, 2004a). Recent in-silico simulations suggest
that the clinical synergism observed for the two antibodies arises
partly from enhanced affinity that originates in cooperative
interactions between the two antibodies when they are colocalised
on HER2 and effectively ‘clamp’ it; this may inhibit dimerisation
and possibly higher oligomerisations with neighbouring receptors
(Fuentes et al, 2011). Another explanation for the synergistic
activity of trastuzumab and pertuzumab is the inhibition of
two different HER2 activation mechanisms; while trastuzumab
inhibits the proteolytic shedding of HER2 ECD, which produces
the constitutively active truncated form p95HER2 (Molina et al,
2001), and ligand-independent formation of HER2:HER3 hetero-
dimers (Junttila et al, 2009), pertuzumab inhibits ligand-activated
HER2 heterodimers (Agus et al, 2002; Franklin et al, 2004; Junttila
et al, 2009).
Phosphorylated p44/p42 MAPK (pERK1/2) was unaltered, while
the combination of trastuzumab and pertuzumab reduced levels of
active pAkt to a greater degree vs either agent alone in BT474 cells
(Nahta et al, 2004a). However, in the current study of ovarian
tumours in vivo, pERK was reduced by all treatments after 7 days
and pAKT was reduced by pertuzumab alone, but not by
trastuzumab or the combination. It has recently been shown that
the response of HER2-amplified AU565, SKBR3 and HCC1569 cells
to these anti-HER2 agents are highly dependent on the 3D
environment and this has a substantial impact on downstream
signalling (Weigelt et al, 2010), which may account for some of the
differences seen in our results and previous in-vitro expression
profiling studies. Comparison of 3D with 2D culture studies
demonstrated a shift in dependency from Akt to ERK dependency
in 3D with a consequent enhancement of growth response to
trastuzumab (Weigelt et al, 2010).
While changes in gene expression can be very useful in
highlighting the genes and pathways induced by the agents, they
were limited to a ‘snapshot’ at day 4 following the initiation of
treatment. We recently showed that the response to tamoxifen in
breast cancer xenografts is a highly dynamic process (Taylor et al,
2010). While further time points would be useful, they obviously
involve the collection of much more material. The protein changes
measured in this study hint at the complex dynamics of the
response to these agents (Figure 3). Some of the primary ovarian
xenografts demonstrate similar responses to combination therapy
as the SKOV3 cells, although there was significant variation,
consistent with the molecular heterogeneity of ovarian tumours
(Marquez et al, 2005; Zorn et al, 2005) and demonstrating the need
to identify robust biomarkers of response. There was distinct
morphological heterogeneity within and between xenografts
following the treatment, with clear cell areas markedly reduced
following the treatment with trastuzumab and significantly
reduced after combination therapy-treated tumours (Faratian
et al, 2011). The molecular response to letrozole in ERþ breast
tumours was found to be homogeneous for responders and
heterogeneous for non-responders (Miller et al, 2009). Whether
the differences in molecular response noted in this study are
disease specific or due to in-vivo rather than in-vitro analysis is not
clear and deserves further investigation. It would be very
interesting to compare gene expression changes with the different
antibodies and combination in a neoadjuvant ‘window study’;
however, it is simply not possible to expose the same tumour to
different regimens as it is with our in-vivo approach. The
intratumoural heterogeneity of HER2 expression may also be a
consideration. Heterogeneity of HER2 expression has been
observed in some gastric cancer specimens (Grabsch et al, 2010)
and mucinous ovarian cancer (McAlpine et al, 2009).
The results in the present study support the hypothesis that
trastuzumab and pertuzumab inhibit different molecular pathways
implied by different HER2 activation mechanisms. In SKOV3 cells,
mechanisms sensitive to trastuzumab inhibition like HER2 ECD
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shedding seem to be prevalent (Figure 2B). This is reflected both in
the more potent growth inhibition by trastuzumab compared with
pertuzumab monotherapy, as well as by the fact that the molecular
changes found in combination treatment are dominated by
trastuzumab. Accordingly, the sensitivity of individual tumours
to trastuzumab and pertuzumab treatment, respectively, may
depend on the expression of HER-family receptors, their ligands,
receptor activating proteases and alternative signalling pathways.
Furthermore, upregulation of HER2 heterodimerisation partners
like HER3 and HER-family ligands like neuregulin during
trastuzumab treatment of HER2-positive tumours suggests the
use of combination treatment early on. Since the combination is
effective both in a serous and in a mixed clear cell/endometrioid
models that have in common amplification of HER2 expression,
our results would suggest that this combination of antibodies is
likely to be most effective in high HER2 expressing ovarian
cancers, irrespective of histology.
In conclusion, a number of previously characterised signalling
pathways are both commonly and distinctly affected by two agents
that target alternative domains of HER2 in ovarian tumours
in vivo. The molecular response to combination treatment
exhibited both common and distinct aspects of single agent
therapy, although overall was more similar to that of trastuzumab
alone.
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